Akero Therapeutics will deliver two oral presentations and a poster at AASLD’s The Liver Meeting 2025, highlighting 96-week Phase 2b data for efruxifermin (EFX) in compensated cirrhosis due to MASH (SYMMETRY) and an AI-enabled digital histology readout from the HARMONY study in pre-cirrhotic MASH. The talks will focus on non-invasive test improvements linked to fibrosis regression and reductions in markers of portal hypertension using Baveno VII criteria in cirrhotic patients, alongside microarchitectural liver changes detected through AI analysis in F2/F3 disease. These updates arrive as EFX advances through three Phase 3 programs spanning histology, outcomes in F4c, and a real-world study.
The editorial question is whether Akero is building the right evidence package to differentiate in a market reshaped by the first MASH approval and growing payer gatekeeping. If SYMMETRY’s 96-week data convincingly show regression signals on non-invasive tests and favorable movement on portal hypertension risk stratification, EFX could be one of the first candidates to credibly address advanced disease where clinical need and cost pressure are highest. That would position Akero beyond a histology-only narrative and towards tangible risk reduction for decompensation, hospitalization, and variceal bleeding—endpoints that resonate with hepatologists and payers alike.
This matters now because the competitive baseline has shifted. The initial approval in MASH established a foothold in F2–F3 disease but did not extend to compensated cirrhosis, leaving a clinical and commercial opening. Companies advancing THR-β agonists, FGF21 analogs, and metabolic incretin strategies are all racing to translate histologic improvements into meaningful outcomes and payer-ready value stories. In that context, Baveno VII-driven analyses are a savvy bridge: while not substitutes for hepatic venous pressure gradient or hard outcomes, they align with how clinicians triage variceal risk and could inform near-term practice and coverage decisions if the signals are durable and reproducible.
For Medical Affairs, the AI-powered histology work speaks to a second industry inflection point: reducing pathologist variability and extracting more granular morphometric signals from biopsies. If AI confirms consistent remodeling of liver microarchitecture with EFX and correlates with non-invasive tests, it strengthens the mechanistic narrative and supports broader adoption of digital pathology in trial design and post-approval evidence generation. It also sets up a pragmatic education agenda for HCPs on linking NITs, digital histology, and clinical decision-making—critical as health systems push to limit biopsies and standardize MASH care pathways.
For Commercial and Market Access teams, durability over 96 weeks is the currency for formulary negotiations. Payers will look for sustained fibrosis regression signals, portal hypertension risk modification, and metabolic comorbidity benefits that translate into near-term budget impact. If Akero can align its outcomes trial in compensated cirrhosis with these intermediate markers, it could underpin outcomes-based contracts and differentiate from agents with narrower labels or less advanced disease focus. Competitors in the FGF21 class, as well as incumbents in THR-β and metabolic incretins, will watch whether Akero’s NIT and digital pathology data tighten the predictive link to clinical events—a potential lever for class positioning.
The forward test is clear: will EFX’s Phase 3 outcomes in F4c validate the non-invasive and Baveno VII signals seen at 96 weeks, and will regulators and payers accept this integrated evidence stack—histology, NITs, AI pathology—as sufficient to expand treatment into compensated cirrhosis at scale?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
